Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia

Dermatologic Therapy

Volumn 25, Issue 6, 2012, Pages 615-618

  Mlika, Rym Benmously ^a   Hamida, Myriam Ben ^a   Hammami, Houda ^a   Jannet, Salima Ben ^a   Badri, Talel ^a   Fenniche, Sami ^a   Mokhtar, Inçaf ^a  

^a UNIVERSITY OF TUNIS   (Tunisia)

Author keywords

cutaneous leishmaniasis; meglumine antimoniate; side effects; Tunisia

Indexed keywords

MEGLUMINE ANTIMONATE;

ADOLESCENT; ADULT; ANEMIA; ASTHENIA; CHILD; COUGHING; DISEASE ASSOCIATION; FEMALE; FEVER; HUMAN; INJECTION SITE ERYTHEMA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUSCULOSKELETAL PAIN; NEUTROPENIA; PRESCHOOL CHILD; RASH; RETROSPECTIVE STUDY; REVIEW; SKIN LEISHMANIASIS; TREATMENT DURATION; TREATMENT OUTCOME; TUNISIA; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUNISIA; YOUNG ADULT;

EID: 84870493787     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2012.01522.x     Document Type: Review

References (15)

1. Mitropoulos P, Konidas P, Konidas MD,. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol 2010: 63: 309-322.
2. Minodiera P, Parolab P,. Cutaneous leishmaniasis treatment. Travel Med Infect Dis 2007: 5: 150-158.
3. Benmously Mlika R, El Aidli S, Ben Brahim M, et al. Effets indésirables du traitement systémique de la leishmaniose cutanée par Glucantime®: expérience tunisienne. Med Trop 2008: 68: 499-501. (Pubitemid 352791644)
4. Masmoudi A, Maaleja N, Mseddia M, et al. Glucantime® injection: benefit versus toxicity. Médecine et Maladies Infectieuses 2005: 35 (1): 42-45. (Pubitemid 40193480)
5. Ezzine Sebai N, Mrabet N, Khaled A, et al. Les effets indésirables du glucantime® par voie générale, dans le traitement de la leishmaniose cutanée: a propos de 15 cas. Tunis Med 2010: 88: 9-11.
6. Hajlaoui K, Zeglaoui F, Ezzine N, et al. Glucantime® reaction with fatal outcome following treatment of cutaneous leishmaniasis. Ann Dermatol Venereol 2008: 135 (4): 317-318.
7. Wortmann G, Miller RS, Oster C, et al. A randomized, doubleblind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 2002: 35: 261-267. (Pubitemid 34800273)
8. McBride MO, Linney M, Davidson RN, et al. Pancreatitis necrosis following treatment of leishmaniasis with sodium stibiogluconate. Clin Infect Dis 1995: 21: 710.
9. Kashani MN, Firooz A, Eskandari SE, et al. Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis. Eur J Dermatol 2007: 17 (6): 513-515. (Pubitemid 350207162)
10. Sadeghian G, Hengamech Z, Masumeh S,. Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime. Ann Acad Med Singapore 2008: 37: 916-918.
11. Buffet P,. Leishmaniose cutanée. EMC (Elsevier Masson SAS, Paris), Dermatologie, 98-395-A-15, 2008.
12. Bailey MS, Lockwood DNJ,. Cutaneous leishmaniasis. Clin Dermatol 2007: 25: 203-211. (Pubitemid 46366603)
13. Ben Salah A, Buffet PA, Morizot G, et al. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 2009: 3: e432. Epub 2009 May 5.
14. Benmously Mlika R, Hammami H, Sioud A, Mokhtar I, Fenniche S,. Lupoid leishmaniasis of the nose responding well to cryotherapy. Dermatol Ther 2011: 24: 378-379.
15. Mosleh IM, Geith E, Natsheh L, Schönian G, Abotteen N, Kharabsheh S,. Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis. J Am Acad Dermatol 2008: 58: 617-624.